Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome

Clinical Microbiology Reviews

Volumn 17, Issue 4, 2004, Pages 926-941

  Tzipori, Saul ^a   Sheoran, Abhineet ^a   Akiyoshi, Donna ^a   Donohue Rolfe, Arthur ^a   Trachtman, Howard ^b  

^a TUFTS UNIVERSITY   (United States)

^b N Shore Long Isl Jewish Res Inst ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CHIMERIC ANTIBODY; DIPYRIDAMOLE; FIBRINOLYTIC AGENT; FOSFOMYCIN; HEPARIN; HUMAN IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; SHIGA TOXIN; STREPTOKINASE; SYNSORB PK; UNCLASSIFIED DRUG; UROKINASE; VEROTOXIN 1; VEROTOXIN 2;

ANIMAL MODEL; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; CLINICAL FEATURE; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATION; MOUSE; PROTEIN STRUCTURE; REVIEW; SWINE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXICITY;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; SHIGA-LIKE TOXIN II; SHIGELLA DYSENTERIAE;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS MUSCULUS; NEGIBACTERIA; PURPURA; SUS SCROFA;

EID: 5644227317     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.17.4.926-941.2004     Document Type: Review

References (142)

1. Andreoli, S. P., H. Trachtman, D. W. K. Acheson, R. L. Siegler, and T. G. Obrig. 2002. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr. Nephrol. 17:293-298.
2. Banatvala, N., P. M. Griffin, K. D. Greene, T. J. Barrett, W. F. Bibb, J. H. Green, and J. G. Wells. 2001. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J. Infect. Dis. 183:1063-1070.
3. Bell, B. P., P. M. Griffin, P. Lozano, D. L. Christie, J. M. Kobayashi, and P. I. Tarr. 1997. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:E12.
4. Bielaszewska, M., H. Schmidt, M. A. Karmali, R. Khakhria, J. Janda, K. Blahova, and H. Karch. 1998. Isolation and characterization of sorbitol-fermenting Shiga toxin (verocytotoxin)-producing Escherichia coli O157:H-strains in the Czech Republic. J. Clin. Microbiol. 36:2135-2137.
5. Bitzan, M., M. Klemt, R. Steffens, and D. E. Muller-Wiefel. 1993. Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection 21:140-145.
6. Bonnet, R., B. Souweine, G. Gauthier, C. Rich, V. Livrelli, J. Sirot, B. Joly, and C. Forestier. 1998. Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults. J. Clin. Microbiol. 36:1777-1780.
7. Bruggemann, M., and M. J. Taussig. 1997. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. 8:455-458.
8. Calderwood, S. B., and J. J. Mekalanos. 1987. Iron regulation of Shiga-like toxin. J. Bacteriol. 169:4759-4764.
9. Chalmers, R. M., S. M. Parry, R. L. Salmon, R. M. Smith, G. A. Willshaw, and T. Cheasty. 1999. The surveillance of vero cytotoxin-producing Escherichia coli O157 in Wales, 1990 to 1998. Emerg. Infect. Dis. 5:566-569.
10. Chandler, W. L., S. Jelacic, D. R. Boster, M. A. Ciol, G. D. Williams, S. L. Watkins, T. Igarashi, and P. I. Tarr. 2002. Prothrombotic coagulation abnormalities preceding the hemolytic uremic syndrome. N. Engl. J. Med. 346:23-32.
11. Chapman, A. P., P. Antoniw, M. Spitali, S. West, S. Stephens, and D. J. King. 1999. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17:780-783.
12. Chowdhury, P. S., and I. Pastan. 1999. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17:568-572.
13. Clark, C., D. Bast, A. Sharp, P. M. St. Hilaire, R. Agha, P. E. Stein, E. J. Toone, R. J. Read, and J. L. Brunton. 1996. Phenylalanine 30 plays an important role in receptor binding of verotoxin-1. Mol. Microbiol. 19:891-899.
14. Cornick, N. A., I. Matise, J. E. Samuel, B. T. Bosworth, and H. W. Moon. 2000. Shiga toxin-producing Escherichia coli infection: temporal and quantitative relationships among colonization, toxin production, and systemic disease. J. Infect. Dis. 181:242-251.
15. Cowan, L. A., D. M. Hertzke, B. W. Fenwick, and C. B. Andreasen. 1997. Clinical and clinicopathologic abnormalities in greyhounds with cutaneous and renal glomerular vasculopathy: 18 cases (1992-1994). J. Am. Vet. Med. Assoc. 210:789-793.
16. Daugherty, P., B. Iverson, and G. Georgiou. 2000. Flow cytometric screening of cell-based libraries. J. Immunol. Methods 243:211-227.
17. Dean-Nystrom, E. A., J. F. Pohlenz, H. W. Moon, and A. D. O'Brien. 2000. Escherichia coli 0157:H7 causes more-severe systemic disease in suckling piglets than in colostrum-deprived neonatal piglets. Infect. Immun. 68:2356-2358.
18. Donohue-Rolfe, A., I. Kondova, S. Oswald, D. Hutto, and S. Tzipori. 2000. Escherichia coli O157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. J. Infect. Dis. 181:1825-1829.
19. Donohue-Rolfe, A., M. Jacewicz, and G. T. Keusch. 1989. Isolation and characterization of functional shiga toxin subunits and renatured holotoxin. Mol. Microbiol. 3:1231-1236.
20. Donohue-Rolfe, A., I. Kondova, J. Mukherjee, K. Chios, D. Hutto, and S. Tzipori. 1999. Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infect. Immun. 67:3645-3648.
21. Edwards, A. C., A. R. Melton-Celsa, K. Arbuthnott, S. J. R., C. K. Schmitt, H. C. Wong, and A. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388-392. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
22. Essher, Z. 1985. Monoclonal antibody strategy and techniques. Plenum Press, New York, N.Y.
23. Fenwich, R. W., and L. A. Cowan. 1998. Canine model of hemolytic uremic syndrome. In Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains, p. 268-277. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
24. Fishwild, D. M., S. L. O'Donnell, T. Bengoechea, D. V. Hudson, F. Harding, S. L. Bernhard, D. Jones, R. M. Kay, K. M. Higgins, S. R. Schramm, and N. Lonberg. 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14:845-851.
25. Francis, D. H., J. E. Collins, and J. R. Dulmstra. 1986. Infection of gnotobiotic pigs with an Escherichia coli O157:H7 strain associated with an outbreak of hemorrhagic colitis. Infect. Immun. 51:953-956.
26. Friedrich, A. W., M. Bielaszewska, W. L. Zhang, M. Pulz, T. Kuczius, A. Ammon, and H. Karch. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185:74-84.
27. Fuchs, S., I. Muhldorfer, A. Donohue-Rolfe, M. Kerenyi, L. Emody, R. Alexiev, P. Nenkov, and J. Hacker. 1999. Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb. Pathog. 27:13-23.
28. Furutani, M., K. Ito, Y. Oku, Y. Takeda, and K. Igarashi. 1990. Demonstration of RNA N-glycosidase activity of a verotoxin (VT2 variant) produced by Escherichia coli 091:H21 from patient with the hemolytic uremic syndrome. Microbiol. Immunol. 34:387-392.
29. Gallo, G., and C. Gianantonio. 1994. Extrarenal involvement in diarrhea-associated haemolytic-uremic syndrome. Pediatr. Nephrol. 9:117-119.
30. Gannon, V. P., C. L. Gyles, and B. P. Wilcock. 1989. Effects of Escherichia coli Shiga-like toxins (verotoxins) in pigs. Can. J. Vet. Res. 53:306-312.
31. Gannon, V. P., C. Teerling, S. A. Masri, and C. L. Gyles. 1990. Molecular cloning and nucleotide sequence of another variant of the Escherichia coli Shiga-like toxin II family. J. Gen. Microbiol. 136:1125-1135.
32. Garcia, A., R. P. Marini, Y. Feng, A. Vitsky, K. A. Knox, N. S. Taylor, D. B. Schauer, and J. G. Fox. 2003. A naturally occurring rabbit model of enterohemorrhagic Escherichia coli-induced disease. J. Infect. Dis. 186:1682-1686.
33. Gasser, C., C. Gautier, R. Steck, et al. 1955. Hamolytisch-uramische syndrome: bilaterle niernindennekrosen bei akuten erworbenen hamolytischen anamkien. Schweiz. Med. Weochenschr. 85:905-909.
34. Gerber, A., H. Karch, F. Allerberger, H. M. Verweyen, and L. B. Zimmerhackl. 2002. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J. Infect. Dis. 15;186:493-500.
35. Gomez, S. A., G. C. Fernandez, S. Vanzulli, G. Dran, C. Rubel, T. Berki, M. A. Isturiz, and M. S. Palermo. 2003. Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome. Clin. Exp. Immunol. 131:217-224.
36. Griffin, P. M., and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13:60-98.
37. Gunzer, F., I. Hennig-Pauka, K. H. Waldmann, R. Sandhoff, H. J. Grone, H. H. Kreipe, A. Matussek, and M. Mengel. 2002. Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. Am. J. Clin. Pathol. 118:364-375.
38. Halloran, P. F., and S. Prommool. 1998. Humanized monoclonals and other biological initiatives. Clin. Biochem. 31:353-357.
39. Hamano, S., Y. Nakanishi, T. Nara, T. Seki, T. Ohtani, T. Oishi, K. Job, T. Oikawa, Y. Muramatsu, Y. Ogawa, and S. Akashi. 1993. Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan. Acta Paediatr. 82:454-458.
40. Harding, F. A., and N. Lonberg. 1995. Class switching in human immunoglobulin transgenic mice. Ann. N.Y. Acad. Sci. 764:536-546.
41. Head, S. C., M. A. Karmali, and C. A. Lingwood. 1991. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. J. Biol. Chem. 266:3617-3621.
42. Head, S. C., M. Petric, S. Richardson, M. Roscoe, and M. A. Karmali. 1988. Purification and characterization of verocytotoxin 2. FEMS Microbiol. Lett. 51:211-216.
43. Hertzke, D. M., L. A. Cowan, P. Schoning, and B. W. Fenwick. 1995. Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet. Pathol. 32:451-459.
44. Heuvelink, A. E., N. C. Van de Kar, T. J. Van Der Velden, H. Chart, and L. A. Monnens. 1999. Verocytotoxin-producing Escherichia coli infection in household members of children with hemolytic-uremic syndrome in the Netherlands. Pediatr. Infect. Dis. J. 18:709-714.
45. Ikeda, K., O. Ida, K. Kimoto, T. Takatorige, N. Nakanishi, and K. Tatara. 1999. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin. Nephrol. 52:357-362.
46. Islam, M. S., and W. H. Stimson. 1990. Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. J. Clin. Lab. Immunol. 33:11-16.
47. Ito, H., A. Terai, H. Kurazono, Y. Takeda, and M. Nishibuchi. 1990. Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. Microb. Pathog. 8:47-60.
48. Jacewicz, M., H. Clausen, E. Nudelman, A. Donohue-Rolfe, and G. T. Keusch. 1986. Pathogenesis of Shigella diarrhea. XI. Isolation of a Shigella toxin-binding glycolipid from rabbit jejunum and Hela cells and its identification as globotriosylceramide. J. Exp. Med. 163:1391-1404.
49. Jackson, M. P., R. J. Neill, A. D. O'Brien, R. K. Holmes, and J. W. Newland. 1987. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin 1 and Shiga-like toxin 2 encoded by bateriophages from Escherichia coli 933. FEMS Microbiol. Lett. 44:109-114.
50. Kaplan, B. A., K. E. Meyers, and S. L. Schulman. 1998. The pathogenesis and treatment of hemolytic uremic syndrome. J. Am. Soc. Nephrol. 9:1126-1133.
51. Kar, N. C. van de, L. A. Monnens, M. A. Karmali, and V. W. van Hinsbergh. 1992. TNF-α and IL-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of HUS. Blood 80:2755-2764.
52. Karmali, M., B. Steele, M. Petric, and C. Lim. 1983. Sporadic cases of haemolytic uremic syndrome associated with faecal cytotoxin and cytotoxin-producing E. coli in stools. Lancet i:619-620.
53. Karpman, D., A. Andreasson, H. Thysell, B. S. Kaplan, and C. Svanborg. 1995. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr. Nephrol. 9:694-699.
54. Kaufman, R. J., L. C. Wasley, A. J. Spiliotes, S. D. Gossels, S. A. Latt, G. R. Larsen, and R. M. Kay. 1985. Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Mol. Cell. Biol. 5:1750-1759.
55. Keusch, G. T., M. Jacewicz, D. W. Acheson, A. Donohue-Rolfe, A. V. Kane, and R. H. McCluer. 1995. Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect. Immun. 63:1138-1141.
56. Kimura, T., M. S. Co, M. Vasquez, S. Wei, H. Xu, S. Tani, Y. Sakai, T. Kawamura, Y. Matsumoto, H. Nakao, and T. Takeda. 2002. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid Hybridomics 21:161-168.
57. Kitov, P. I., J. M. Sadowska, G. Mulvey, G. Armstrong, H. Ling, N. S. Pannu, R. J. Read, and D. R. Bundle. 2000. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403:669-672.
58. Kleanthous, H., H. R. Smith, S. M. Scotland, R. J. Gross, B. Rowe, C. M. Taylor, and D. V. Milford. 1990. Haemolytic uraemic syndromes in the British Isles, 1985-1988: Association with verocytotoxin producing Escherichia coli. 2. Microbiological aspects. Arch. Dis. Child. 65:722-727.
59. Lingwood, C. A. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4:147-153.
60. Lingwood, C. A. 1994. Verotoxin-binding in human renal sections. Nephron 66:21-28.
61. Lonberg, N., and D. Huszar. 1995. Human antibodies from transgenic mice. Int. Rev. Immunol. 13:65-93.
62. Lonberg, N., L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins, S. R. Schramm, C. C. Kuo, R. Mashayekh, K. Wymore, J. G. McCabe, et al. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859.
63. Louise, C. B., and T. G. Obrig. 1995. Specfiic interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J. Infect. Dis. 172:1397-1401.
64. Ludwig, K., E. Grabhorn, M. Bitzan, C. Bobrowski, M. J. Kemper, I. Sobottka, R. Laufs, H. Karch, and D. E. Muller-Wiefel. 2002. Saliva IgM and IgA are a sensitive indicator of the humoral immune response to Escherichia coli O157 lipopolysaccharide in children with enteropathic hemolytic uremic syndrome. Pediatr. Res. 52:307-313.
65. Mackenzie, A. M. R., P. Rowe, and P. McLaine. 2000. Stx1 and Stx2 among STEC-producing strains isolated from sporadic cases of HUS in Canada (personal communication).
66. MacLeod, D. L., C. L. Gyles, and B. P. Wilcock. 1991. Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet. Pathol. 28:66-73.
67. Mainil, J. 1999. Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals. Vet. Res. 30:235-257.
68. Malmborg, A. C., and C. A. Borrebaeck. 1995. BIAcore as a tool in antibody engineering. J. Immunol. Methods 183:7-13.
69. Marks, J. D., A. D. Griffiths, M. Malmqvist, T. P. Clackson, J. M. Bye, and G. Winter. 1992. By-passing immunization building high affinity human antibodies by chain shuffling. Biotechnology 10:779-783.
70. Marques, L. R. M., J. S. M. Peiris, S. J. Cryz, and A. D. O'Brien. 1987. Escherichia coli strains isolated from pigs with edema disease produce a variant of Shiga-like toxin II. FEMS Microbiol. Lett. 44:281-283.
71. Matise, I., N. A. Cornick, S. L. Booher, J. E. Samuel, B. T. Bosworth, and H. W. Moon. 2001. Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli. J. Infect. Dis. 183:347-350.
72. Maynard, J., and G. Georgiou. 2000. Antibody engineering. Annu. Rev. Biomed. Eng. 2:339-376.
73. Mead, S. P., L. Slutsker, V. Dietz, L. F. McCaig, J. S. Bresee, G. Shapiro, P. M. Griffin, and R. V. Tauxe. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625.
74. Melton-Celsa, A. R., J. E. Rogers, C. K. Schmitt, S. C. Darnell, and A. D. O'Brien. 1998. Virulence of Shiga toxin-producing Escherichia coli (STEC) in orally-infected mice correlates with the type of toxin produced by the infecting strain. Jpn. J. Med. Sci. Biol. 51:S108-114.
75. Meyer, T., H. Karch, J. Hacker, H. Bocklage, and J. Heesemann. 1992. Cloning and sequencing of a Shiga-like toxin II-related gene from Escherichia coli O157:H7 strain 7279. Zentralbl. Bakteriol. 276:176-188.
76. Milford, D. V., C. M. Taylor, B. Guttridge, S. M. Hall, B. Rowe, and H. Kleanthous. 1990. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. 1. Clinical and epidemiological aspects. Arch. Dis. Child. 65:716-721.
77. Moxley, R. A., and D. H. Francis. 1998. Overview of animal models, p. 249-260. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
78. Mühldorfer, I., J. Hacker, G. T. Keusch, D. W. Acheson, H. Tschäpe, A. V. Kane, A. Ritter, T. Ölschläger, and A. Donohue-Rolfe. 1996. Regulation of the Shiga-like toxin operon in Escherichia coli. Infect. Immun. 64:495-502.
79. Mukherjee, J., K. Chios, D. M. Fishwild, D. Hudson, S. L. O'Donnell, S. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
80. Mukherjee, J., K. Chios, D. M. Fishwild, D. Hudson, S. L. O'Donnell, S. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Production and characterization of protective human antibodies against Shiga toxin 1 (Stx1). Infect. Immun. 70:5896-5899.
81. Nakajima, H., N. Kiyokawa, Y. U. Katagiri, T. Taguchi, T. Suzuki, T. Sekino, K. Mimori, T. Ebata, M. Saito, H. Nakao, T. Takeda, and J. Fujimoto. 2001. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J. Biol. Chem. 276:42915-42922.
82. Neely, M. N., and D. I. Friedman. 1998. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol. Microbiol. 28:1255-1267.
83. Nicholson, I. C., X. Zou, A. V. Popov, G. P. Cook, E. M. Corps, S. Humphries, C. Ayling, B. Goyenechea, J. Xian, M. J. Taussig, M. S. Neuberger, and M. Bruggemann. 1999. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J. Immunol. 163:6898-6906.
84. Nishikawa, K., K. Matsuoka, E. Kita, N. Ojkabe, M. Mizuguchi, K. Hino, S. Miyazawa, C. Yamasaki, J. Aoki, S. Takashima, Y. Yamakawa, M. Nishijima, D. Terunuma, H. Kuzuhara, and Y. Natori. 2002. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA 99:7669-7674.
85. Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99:11346-11350.
86. O'Brien, A. D., J. W. Newland, S. F. Miller, R. K. Holmes, H. W. Smith, and S. B. Formal. 1984. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis of infantile diarrhea. Science 226:694-696.
87. O'Brien, A. D., V. L. Tesh, A. Donohue-Rolfe, M. P. Jackson, S. Olsnes, K. Sandvig, A. A. Lindberg, and G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:65-94.
88. Obrig, T. G., P. J. Del Vecchio, J. E. Brown, T. P. Moran, B. M. Rowland, T. K. Judge, and S. W. Rothman. 1988. Direct cytotoxic action of Shiga toxin in human vascular endothelial cells. Infect. Immun. 56:2373-2378.
89. Ostroff, S. M., P. I. Tarr, M. A. Neill, J. H. Lewis, N. Hargrett-Bean, and J. M. Kobayashi. 1989. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis. 160:994-998.
90. Padhye, V. V., T. Zhao, and M. P. Doyle. 1989. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O157:H7. J. Med. Microbiol. 30:219-226.
91. Page, M. J., and M. A. Sydenham. 1991. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology (N.Y.) 9:64-68.
92. Paton, A. W., R. Morona, and J. C. Paton. 2000. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 6:265-270.
93. Paton, A. W., J. C. Paton, M. W. Heuzenroeder, P. N. Goldwater, and P. A. Manning. 1992. Cloning and nucleotide sequence of a variant Shiga-like toxin II gene from Escherichia coli OX3:H21 isolated from a case of sudden infant death syndrome. Microb. Pathog. 13:225-236.
94. Paton, A. W., J. C. Paton, P. N. Goldwater, M. W. Heuzenroeder, and P. A. Manning. 1993. Sequence of a variant Shiga-like toxin type-I operon of Escherichia coli O111:H. Gene 129:87-92.
95. Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11:450-479.
96. Pavia, A., C. R. Nichols, D. P. Green, R. V. Tauxe, S. Mottice, K. D. Greene, J. G. Wells, R. L. Siegler, E. D. Brewer, D. Hannon, et al. 1990. Hemolytic uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiological observations. J. Pediatr. 116:544-551.
97. Pedley, R. B., J. A. Boden, R. Boden, R. H. J. Begent, A. Turner, A. M. R. Haines, and D. J. King. 1994. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer 70:1126-1130.
98. Perera, L. P., L. R. Marques, and A. D. O'Brien. 1988. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J. Clin. Microbiol. 26:2127-2131.
99. Perez, N., F. Spizziri, R. Rahman, A. Suarez, C. Larrubia, and P. Lasarte. 1998. Steroids in hemolytic uremic syndrome. Pediatr. Nephrol. 12:101-104.
100. Pierard, D., G. Muyldermans, L. Moriau, D. Stevens, and S. Lauwers. 1998. Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J. Clin. Microbiol. 36:3317-3322.
101. Proulx, F., J. Turgeon, G. Delage, L. Lafleur, and L. Chicoine. 1992. Randomized controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J. Pediatr. 121:299-303.
102. Raife, T., and R. Montgomery. 2001. New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Rev. Clin. Exp. Hematol. 5:236-261.
103. Ramachandran, V., M. A. Hornitzky, K. A. Bettelheim, M. J. Walker, and S. P. Djordjevic. 2001. The common ovine Shiga toxin 2-containing Escherichia coli serotypes and human isolates of the same serotypes possess an Stx2d toxin type. J. Clin. Microbiol. 39:1932-1937.
104. Ray, P. E., and X. H. Liu. 2001. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr. Nephrol. 16:823-839.
105. Reichert, J. M. 2002. Therapeutic monoclonal antibodies: trends in development and approval in the U.S. Curr. Opin. Mol. Ther. 4:110-118.
106. Reisbig, R., S. Olsnes, and K. Eiklid. 1981. The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60S ribosomal subunit. J. Biol. Chem. 256:8739-8744.
107. Robson, W. L. M., G. H. Fick, T. Jadavji, and A. K. Leung. 1991. The use of intravenous gammaglobulin in the treatment of atypical hemolytic uremic syndrome. Pediatr. Nephrol. 5:289-292.
108. Russmann, H., H. Schmidt, J. Heesemann, A. Caprioli, and H. Karch. 1994. Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J. Med. Microbiol. 40:338-343.
109. Safdar, N., A. Said, R. E. Gangnon, and D. G. Maki. 2002. Risk of hemolytic uremic syndrome after antibiotic therapy of Escherichia coli O157:H7 enteritis. JAMA 288:996-1001.
110. Schmidt, H., J. Scheef, S. Morabito, A. Caprioli, L. H. Wieler, and H. Karch. 2000. A new Shiga toxin 2 variant (Srx2f) from Escherichia coli isolated from pigeons. Appl. Environ. Microbiol. 66:1205-1208.
111. Schmitt, C. K., M. L. McKee, and A. D. O'Brien. 1991. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H-strain E32511. Infect. Immun. 59:1065-1073.
112. Scotland, S. M., G. A. Willshaw, H. R. Smith, and B. Rowe. 1987. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol. Infect. 99:613-624.
113. Sheoran, A. S., S. Chapman, P. Singh, A. Donohue-Rolfe, and S. Tzipori. 2003. Stx2-spcific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect. Immun. 71:3125-3130.
114. Shimizu, H., R. A. Field, S. W. Homans, and A. Donohue-Rolfe. 1998. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry 37:11078-11082.
115. Siegler, R. L., T. J. Pysher, R. Lou, V. L. Tesh, and F. B. Taylor, Jr. 2001. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Am. J. Nephrol. 21:420-425.
116. Siegler, R. L. 1994. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J. Pediatr. 125:511-518.
117. Slutsker, L., A. A. Ries, K. Maloney, J. G. Wells, K. D. Greene, and P. M. Griffin. 1998. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J. Infect. Dis. 177:962-966.
118. Strockbine, N. A., L. R. Marques, R. K. Holmes, and A. D. O'Brien. 1985. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect. Immun. 50:695-700.
119. Tarr, P. I., and M. A. Neill. 2001. Escherichia coli O157:H7. Gastroenterol. Clin. North Am. 30:735-751.
120. Tarr, P. I. 1995. Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin. Infect. Dis. 20:1-8.
121. Taylor, L. D., C. E. Carmack, S. R. Schramm, R. Mashayekh, K. M. Higgins, C. C. Kuo, C. Woodhouse, R. M. Kay, and N. Lonberg. 1992. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 20:6287-6295.
122. Te Loo, D. M. W. M., V. W. M. van Hinsbergh, L. P. W. J. van den Heuvel, and L. A. H. Monnens. 2001. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12:800-806.
123. Tesh, V. L., J. A. Burris, J. W. Owens, V. M. Gordon, E. A. Wadolkowski, A. D. O'Brien, and J. E. Samuel. 1993. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61:3392-3402.
124. Thomas, A., T. Cheasty, H. Chart, and B. Rowe. 1994. Isolation of Vero cytotoxin-producing Escherichia coli serotypes O9ab:H- and O101:H-carrying VT2 variant gene sequences from a patient with haemolytic uraemic syndrome. Eur. J. Clin. Microbiol. Infect. Dis. 13:1074-1076.
125. Trachtman, H., and C. Christen. 1999. Hemolytic uremic syndrome: current understanding of the pathogenesis and therapeutic trials and interventions. Curr. Opin. Pediatr. 11:162-168.
126. Trachtman, H., A. Cnaan, E. Christen, K. Gibbs, S. Zhao, D. W. Acheson, R. Weiss, F. J. Kaskel, A. Spitzer, and G. H. Hirschman. 2003. Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 10:1337-1344.
127. Tuaillon, N., L. D. Taylor, N. Lonberg, P. W. Tucker, and J. D. Capra. 1993. Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts. Proc. Natl. Acad. Sci. USA 90:3720-3724.
128. Tzipori, S., K. I. Wachsmuth, and C. Chapman. 1986. Studies on the pathogenesis of haemorrhagic colitis by Escherichia coli O157:H7 in gnotobiotic piglets. J. Infect. Dis. 154:712-716.
129. Tzipori, S., F. Gunzer, L. de Montigny, M. Donnenberg, J. Kaper, and A. Donohue-Rolfe. 1995. The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect. Immun. 63:3621-3627.
130. Tzipori, S., C. W. Chow, and H. R. Powell. 1988. Cerebral involvement with Escherichia coli O157:H7 in humans and gnotobiotic piglets. J. Clin. Pathol. 41:1099-1103.
131. Tzipori, S., H. Karch, K. I. Wachsmuth, R. M. Robins-Browne, A. D. O'Brien, H. Lior, M. L. Cohen, J. Smithers, and M. M. Levine. 1987. Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect. Immun. 55:3117-3125.
132. Tzipori, S., R. Gibson, and J. Montanaro. 1989. Nature and distribution of mucosal lesions associated with enteropathogenic and enterohemorrhagic Escherichia coli in piglets and the role of plasmid-mediated factors. Infect. Immun. 57:1142-1150.
133. Van Setten, P. A., V. W. M. Van Hinsbergh, L. P. W. J. Van Den Heuvel, F. Preyers, H. B. P. M. Dijkman, K. J. M. Assmann, T. J. A. M. Van Der Velden, and L. A. H. Monnens. 1998. Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patients with hemolytic uremic syndrome. Pediatr. Res. 43:759-767.
134. Verma, R., E. Boleti, and A. J. T. George. 1998. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216:165-181.
135. Wadolkowski, E. A., J. A. Burns, and A. D. O'Brien. 1990. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect. Immun. 58:2438-2445.
136. Wang, H., E. Christen, K. J. Tracey, and H. Trachtman. 2001. HMG-1 excretion is increased in children with diarrheal-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12:185A (abstract).
137. Weinstein, D. L., M. P. Jackson, J. E. Samuel, R. K. Holmes, and A. D. O'Brien. 1988. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine. J. Bacteriol. 170:4223-4230.
138. Wong, C. S., S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr. 2000. The risk of hemolytic-uremic syndrome after antibiotic therapy of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342:1930-1936.
139. Wood, C. R., A. J. Dorner, G. E. Morris, E. M. Alderman, D. Wilson, R. M. O'Hara, Jr., and R. J. Kaufman. 1990. High level synthesis of immunoglobulins in Chinese hamster ovary cells. J. Immunol. 145:3011-3016.
140. Woods, J. B., C. K. Schmitt, S. C. Darnell, K. C. Meysick, and A. D. O'Brien. 2002. Ferrets as a model system for renal disease secondary to intestinal infection with Escherichia coli O157:H7 and other Shiga toxin-producing E. coli. J. Infect. Dis. 185:550-554.
141. Yamagami, S., M. Motoki, T. Kimura, H. Izumi, T. Takeda, Y. Katsuura, and Y. Matsumoto. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738-742.
142. Zhang, X., A. D. McDaniel, L. E. Wolf, G. T. Keusch, M. K. Waldor, and D. W. K. Acheson. 2000. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181:664-670.